SCHEMBL4615604

SCHEMBL4615604

Cc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)N1CCN(CCN2CCOCC2)CC1

nearest known ligand 0.82

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.82
SMN1; SMN2 Q16637 2/20 0.82
L3MBTL1 Q9Y468 2/20 0.82
LMNA P02545 3/20 0.66
TSHR P16473 2/20 0.60
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MAPK1 P28482 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PIK3CA P42336 1/20 0.48
MTOR P42345 1/20 0.48
RAB9A P51151 1/20 0.48
REV1 Q9UBZ9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616587 0.97 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4617911 0.92 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4616470 0.88 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4616398 0.87 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4616150 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4616193 0.84 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4618904 0.82 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2L3MBTL1TSHRMAPK1
SCHEMBL4638749 0.81 SFRP1 (0.66) ALDH1A1SMN1; SMN2L3MBTL1TSHRNPSR1
SCHEMBL4617917 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4617036 0.79 SFRP1 (0.64) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 ALDH1A1 1865/4885SMN1; SMN2 2404/4885L3MBTL1 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.